Evidence map›Paper›PMID 41154472›Full record

ArticleAntioxidants (Basel, Switzerland)2025

Investigating the Molecular Impact of GGMSC on Redox and Metabolic Pathways in Pancreatic Cancer Cells.

Arun Kumar Selvam, Mehran Ghaderi, Joakim Dillner, Shaheen Majeed, Mikael Björnstedt

Abstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Arun Kumar SelvamDepartment of Laboratory Medicine, Division of Pathology F46, Karolinska University Hospital Huddinge, SE-141 86 Stockholm, Sweden.ORCID 0000-0002-9854-2048
Mehran GhaderiDepartment of Clinical Science, Intervention and Technology (CLINTEC), ANA Futura, Karolinska Institutet, SE-141 52 Stockholm, Sweden.ORCID 0000-0002-5396-6023
Joakim DillnerDepartment of Clinical Science, Intervention and Technology (CLINTEC), ANA Futura, Karolinska Institutet, SE-141 52 Stockholm, Sweden.
Shaheen MajeedSabinsa Corporation, 20 Lake Drive, East Windsor, NJ 08520, USA.ORCID 0000-0001-6400-8245
Mikael BjörnstedtDepartment of Laboratory Medicine, Division of Pathology F46, Karolinska University Hospital Huddinge, SE-141 86 Stockholm, Sweden.ORCID 0000-0003-2831-3837

Funding

ALF RS2020-0731Cancerfonden 23 2796Pj 01 HCancer och Allergifonden 2025Center for Innovative Medicine FoUI-976014Radiumhemmets Forskningsfounder 231082
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains a highly aggressive malignancy with limited treatment options. Targeting metabolic vulnerabilities and disrupting redox stress pathways has gained increasing attention as a potential therapeutic strategy. γ-Glutamyl-selenomethylselenocysteine (GGMSC) is a selenium-containing compound structurally related to seleno-L-methylselenocysteine (MSC), which has shown anticancer potential in preclinical models, although its molecular effects in PDAC are not well defined. In this study, we investigated the transcriptomic response to high-dose GGMSC in two PDAC cell lines, CAPAN-2 and HPAF-II. RNA sequencing and cytotoxicity assays revealed marked sensitivity to GGMSC in CAPAN-2 cells, associated with activation of oxidative stress and ferroptosis-related pathways, alongside downregulation of metabolic and cell cycle genes. Conversely, HPAF-II cells displayed limited transcriptional alterations and maintained proliferative and metabolic programs. These findings offer insights into the molecular mechanisms underlying GGMSC-induced transcriptional responses in PDAC and suggest potential avenues for future investigations of selenium-based therapies in pancreatic cancer.

Indexed as

epigenetic modificationferroptosisgamma-glutamyl-selenomethylselenocysteinepancreatic ductal adenocarcinomaredox regulationselenium cytotoxicity

Identifiers

PMID41154472
PMCPMC12561508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.